par Vanlaethem, Yves ;Cran, Sophie;Van de Perre, Philippe
Référence Current therapeutic research, 41, 2, page (244-253)
Publication Publié, 1987
Article révisé par les pairs
Résumé : Aztreonam is a new monobactam antibiotic with high in vitro activity restricted to aerobic gram-negative bacteria. Eighteen patients were treated in an open clinical study with aztreonam 3 to 6 gm intravenously/day. Mean duration of therapy was 12 days. All patients presented with severe underlying disases. Fifteen patients suffered from a gram-negative septicemia, and the three others presented with non-septicemic Pseudomonas aeruginosa infections. Overall cure rate of nonpseudomonal infections was 93%. One of four infections due to P aeruginosa was cured. Only minor side effects were observed: transient increases in liver tests (33%) and phlebitis (11%). Aztreonam was shown to be a promising drug in severe gram-negative infections.